Forte Biosciences, Inc. (NASDAQ:FBRX - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors bought 30,205 call options on the stock. This is an increase of 1,663% compared to the typical volume of 1,713 call options.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on FBRX shares. TD Cowen began coverage on shares of Forte Biosciences in a report on Tuesday, January 21st. They issued a "buy" rating on the stock. Chardan Capital reissued a "buy" rating and issued a $64.00 target price on shares of Forte Biosciences in a research note on Wednesday, December 4th.
Read Our Latest Stock Report on Forte Biosciences
Institutional Investors Weigh In On Forte Biosciences
Several institutional investors and hedge funds have recently made changes to their positions in FBRX. JPMorgan Chase & Co. lifted its holdings in Forte Biosciences by 70,000.0% during the 4th quarter. JPMorgan Chase & Co. now owns 2,103 shares of the company's stock valued at $48,000 after purchasing an additional 2,100 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Forte Biosciences by 18.3% during the fourth quarter. Geode Capital Management LLC now owns 16,877 shares of the company's stock worth $383,000 after buying an additional 2,607 shares in the last quarter. Acuta Capital Partners LLC bought a new position in shares of Forte Biosciences in the fourth quarter valued at approximately $412,000. Boothbay Fund Management LLC acquired a new position in shares of Forte Biosciences in the 4th quarter worth approximately $2,026,000. Finally, Woodline Partners LP bought a new stake in Forte Biosciences during the 4th quarter worth approximately $4,639,000. Institutional investors and hedge funds own 77.63% of the company's stock.
Forte Biosciences Trading Up 2.6 %
FBRX stock traded up $0.28 during trading on Friday, hitting $10.98. The company had a trading volume of 12,019 shares, compared to its average volume of 26,876. The company has a fifty day moving average price of $16.56 and a two-hundred day moving average price of $10.76. Forte Biosciences has a fifty-two week low of $4.11 and a fifty-two week high of $28.68. The company has a market cap of $70.16 million, a P/E ratio of -0.67 and a beta of 1.09.
Forte Biosciences Company Profile
(
Get Free Report)
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Featured Stories
Before you consider Forte Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Forte Biosciences wasn't on the list.
While Forte Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
